Emestop 40 mg (Capsule)

Unit Price: ৳ 50.00 (1 x 4: ৳ 200.00)
Strip Price: ৳ 200.00

Medicine Details

Category Details
Generic Aprepitant
Company Incepta pharmaceuticals ltd
Also available as

Title

  • Emestop

Categories

  • Medicine
  • Health
  • Pharmacology
  • Antiemetic

Description

  • Emestop is indicated for prevention of postoperative nausea and vomiting (PONV) and prevention of Chemotherapy Induced Nausea and Vomiting (CINV). Aprepitant, the active ingredient, is a selective high affinity antagonist of human substance P neurokinin 1 (NK1) receptors, which blocks the receptors to prevent nausea and vomiting. It is available in various dosage regimens for different indications. Emestop is a substrate, a weak-to-moderate inhibitor, and an inducer of CYP3A4, and an inducer of CYP2C9, and should be stored below 30°C, away from light & moisture.

Dimensions

  • N/A

Color options

  • N/A

Functions

  • Prevention of postoperative nausea and vomiting (PONV)
  • Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)

Materials

  • Aprepitant

Technical specifications

  • Aprepitant 40 mg oral dosage within 3 hours prior to induction of anesthesia for PONV
  • Aprepitant 125 mg orally, Dexamethasone 12 mg orally, 5-HT3 antagonist (Ondansetron) regimen for highly emetogenic cancer chemotherapy for CINV
  • Aprepitant 80 mg orally, Dexamethasone 8 mg orally regimen for moderately emetogenic cancer chemotherapy for CINV

Design elements

  • N/A

Usability features

  • May be taken with or without food
  • No dosage adjustment necessary for elderly patients
  • No dosage adjustment necessary for patients with renal impairment or end-stage renal disease (ESRD) undergoing hemodialysis
  • No dosage adjustment necessary for patients with mild to moderate hepatic impairment

Interaction

  • Emestop is a substrate, a weak-to-moderate (dose dependent) inhibitor, and an inducer of CYP3A4
  • Emestop is also an inducer of CYP2C9
  • Precautions should be taken while coadministering Emestop with drugs that use CYP3A4 or CYP2C9
  • Coadministration may affect the efficacy of hormonal contraceptives, alternative or back-up methods of contraception should be used during treatment with Emestop and for 1 month following the last dose

Contraindications

  • Hypersensitivity to any component of the product
  • Concurrent use with Pimozide, Terfenadine, Astemizole, & Cisapride

Side effects

  • Constipation
  • Hypotension
  • Pruritus
  • Pyrexia

Pregnancy lactation

  • Pregnancy Category B
  • Use during pregnancy only if clearly needed
  • Not known whether excreted in human milk
  • Decision to discontinue nursing or drug based on patient's importance

Special populations

  • No dosage adjustment necessary for patients with renal impairment or ESRD undergoing hemodialysis
  • No dosage adjustment necessary for patients with mild to moderate hepatic impairment
  • No clinical data in patients with severe hepatic impairment

Overdose effects

  • No specific information available on the treatment of overdosage with Emestop
  • Drowsiness and headache may result from overdose
  • Emestop should be discontinued in the event of overdose
  • General supportive treatment and monitoring should be provided
  • Medicine-induced emesis may not be effective due to antiemetic activity of Emestop
  • Emestop cannot be removed by hemodialysis

Therapeutic class

  • Anti-emetic drugs

Storage conditions

  • Keep below 30°C temperature
  • Away from light & moisture
  • Keep out of the reach of children

Related Brands